These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19464533)

  • 1. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.
    McGowen AL; Hale LP; Shelburne CP; Abraham SN; Staats HF
    Vaccine; 2009 Jun; 27(27):3544-52. PubMed ID: 19464533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.
    Gwinn WM; Johnson BT; Kirwan SM; Sobel AE; Abraham SN; Gunn MD; Staats HF
    Vaccine; 2013 Mar; 31(11):1480-9. PubMed ID: 23352329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
    Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
    J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
    Bielinska AU; Janczak KW; Landers JJ; Makidon P; Sower LE; Peterson JW; Baker JR
    Infect Immun; 2007 Aug; 75(8):4020-9. PubMed ID: 17502384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
    Zeng L; Liu Y; Wang H; Liao P; Song Z; Gao S; Wu Y; Zhang X; Yin Y; Xu W
    Vaccine; 2015 Feb; 33(8):1008-16. PubMed ID: 25595867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
    Sloat BR; Cui Z
    Pharm Res; 2006 Jun; 23(6):1217-26. PubMed ID: 16718616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.
    Kachura MA; Hickle C; Kell SA; Sathe A; Calacsan C; Kiwan R; Hall B; Milley R; Ott G; Coffman RL; Kanzler H; Campbell JD
    J Immunol; 2016 Jan; 196(1):284-97. PubMed ID: 26608924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
    Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
    Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination.
    Bento D; Staats HF; Borges O
    Vaccine; 2015 Jul; 33(31):3609-13. PubMed ID: 26087299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Needle-free skin patch vaccination method for anthrax.
    Matyas GR; Friedlander AM; Glenn GM; Little S; Yu J; Alving CR
    Infect Immun; 2004 Feb; 72(2):1181-3. PubMed ID: 14742571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.
    Martin TL; Jee J; Kim E; Steiner HE; Cormet-Boyaka E; Boyaka PN
    Vaccine; 2017 Apr; 35(18):2511-2519. PubMed ID: 28343781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BA3338, a surface layer homology domain possessing protein augments immune response and protection efficacy of protective antigen against Bacillus anthracis in mouse model.
    Kumar M; Puranik N; Varshney A; Tripathi N; Pal V; Goel AK
    J Appl Microbiol; 2020 Aug; 129(2):443-452. PubMed ID: 32118336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
    Park YS; Lee JH; Hung CF; Wu TC; Kim TW
    Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.
    Gorantala J; Grover S; Goel D; Rahi A; Jayadev Magani SK; Chandra S; Bhatnagar R
    Vaccine; 2011 Jun; 29(27):4521-33. PubMed ID: 21504775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model.
    Ndumnego OC; Köhler SM; Crafford J; van Heerden H; Beyer W
    Vet Immunol Immunopathol; 2016 Oct; 178():14-21. PubMed ID: 27496738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine.
    Mikszta JA; Dekker JP; Harvey NG; Dean CH; Brittingham JM; Huang J; Sullivan VJ; Dyas B; Roy CJ; Ulrich RG
    Infect Immun; 2006 Dec; 74(12):6806-10. PubMed ID: 17030580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice.
    Wui SR; Kim HK; Han JE; Kim JM; Kim YH; Chun JH; Cho YJ; Lee NG
    Int Immunopharmacol; 2011 Sep; 11(9):1195-204. PubMed ID: 21492746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.
    Abboud N; Casadevall A
    Clin Vaccine Immunol; 2008 Jul; 15(7):1115-23. PubMed ID: 18480236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax.
    Chen Z; Schneerson R; Lovchik JA; Dai Z; Kubler-Kielb J; Agulto L; Leppla SH; Purcell RH
    Clin Vaccine Immunol; 2015 Aug; 22(8):902-8. PubMed ID: 26041039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.